07 August 2026
07 August 2026
The approval means mFlusiva becomes the first mRNA-based vaccine to be authorised on the US market for flu prevention.
GlobalData analysts previously flagged Orzeyful’s approval as a key Q3 catalyst for the pharma industry due to the drug’s ‘transformative’ potential.
Alongside Alkeus, several companies like Belite Bio, Ocugen and Nanoscope are aiming to secure a place on the Stargardt market where there are no approved therapies.
The biotech will now focus on the two other BiTEs in its pipeline, CTIM-76 and CT-202.
The partnership gives Ono the exclusive option to license worldwide rights to develop the therapeutic programmes.
The partnership intends to leverage complementary scientific strengths to boost early-stage research and produce new medicines.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
